Denise Keegan
Adult Health · Phil, PANPI 1770660698
Payments from drug & device makers
Across 81 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$305
- Esperion Therapeutics, Inc.$147
- AstraZeneca$140
- Bayer$117
- AbbVie$109
- Abbott$93
- plus $583 from 15 others
What the payments were for
- Food & beverage$1,494100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $305 |
| Esperion Therapeutics, Inc. | 8 | $147 |
| AstraZeneca | 3 | $140 |
| Bayer | 6 | $117 |
| AbbVie | 7 | $109 |
| Abbott | 6 | $93 |
| Lilly USA, LLC | 6 | $91 |
| Pfizer | 5 | $78 |
| GSK | 4 | $72 |
| Dynavax Technologies Corporation | 1 | $61 |
| Boston Scientific | 2 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Boehringer Ingelheim | 1 | $31 |
| Amgen | 2 | $28 |
| Lundbeck LLC | 2 | $27 |
| Dexcom, Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Scpharmaceuticals Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$115
How this compares
$1,494 in reported general payments places this provider in the 70th percentile of 899 adult health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $65,111 |
| JardianceEmpagliflozin | 41 | $52,960 |
| JanuviaSitagliptin Phosphate | 30 | $41,843 |
| EliquisApixaban | 43 | $37,246 |
| FarxigaDapagliflozin Propanediol | 28 | $23,233 |
| ProliaDenosumab | 13 | $22,674 |
| MounjaroTirzepatide | 12 | $12,600 |
| Rosuvastatin Calcium | 593 | $11,829 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $10,177 |
| MultaqDronedarone Hcl | 12 | $9,414 |
| Spiriva RespimatTiotropium Bromide | 12 | $8,986 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $6,956 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $5,475 |
| Levothyroxine Sodium | 333 | $5,431 |
| Losartan Potassium | 326 | $4,761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $305 | $65,11155 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $31 | $61,94653 claims |
| PfizerEliquis | $78 | $37,24643 claims |
| AstraZenecaFarxiga | $140 | $23,23328 claims |
| AmgenProlia | $28 | $22,67413 claims |
| Lilly USA, LLCMounjaro | $91 | $12,60012 claims |
| GSKBreo Ellipta | $72 | $10,17723 claims |
| Esperion Therapeutics, Inc.Nexlizet | $147 | $6,95614 claims |
| AbbVieSynthroid | $109 | $1,65430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Phil
- Beth SandyPhiladelphia$924K
- Diane NewmanPhiladelphia$413K
- Jennifer MondilloSchwenksville$396K
- Elizabeth FaustDouglassville$356K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Lauren MassimoPhiladelphia$139K
- Jennifer KeeleyWexford$97K
- Debra EvansFarrell$85K
- Bethann MallonBlue Bell$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.